Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare and digital health company focused on portable, semiconductor-based ultrasound technology and ultrasound software solutions. The Butterfly Network news feed on Stock Titan highlights company announcements that relate to its handheld ultrasound devices, Ultrasound-on-Chip™ semiconductor platform, enterprise software and AI initiatives.
Investors and healthcare professionals following BFLY news will see updates on financial results and guidance, such as quarterly earnings releases and preliminary revenue expectations furnished through press releases and 8-K filings. These items often include commentary on revenue growth, cash usage, chip development milestones and the progress of enterprise offerings like Compass™ and Compass AI™.
News coverage also features product and platform developments, including launches of new software capabilities such as Compass AI, announcements about AI-enabled clinical tools like Auto B-line Counter or a Gestational Age AI tool, and information about developer-focused initiatives like Butterfly Garden™ and the planned Beam Steering API. These stories provide insight into how Butterfly is expanding its imaging platform and exposing core capabilities to partners and developers.
Another recurring theme in Butterfly Network news is global health and clinical impact. Press releases describe programs in Sub-Saharan Africa involving handheld probes, training and AI tools for obstetric ultrasound, as well as clinical publications that examine how Butterfly’s devices and software can affect workflows, costs and provider economics in hospital systems.
In addition, the BFLY news stream includes capital markets and corporate updates, such as participation in healthcare investor conferences, executive appointments and SEC-reported events like the NYSE’s decision to delist Butterfly’s public warrants while leaving the common stock listing under BFLY unchanged. For readers tracking Butterfly Network, this page offers a consolidated view of operational, financial, technological and regulatory developments as they are publicly disclosed.
Butterfly Network (NYSE:BFLY) launched Compass AI on November 17, 2025 — an AI-powered enterprise platform to manage scalable, revenue-ready point-of-care ultrasound (POCUS) programs.
Key claims: documentation compliance up to 94% (vs ~15% for traditional workflows), up to 5x more revenue from the same clinical volume, and charting time cut by up to 25%. Features include ambient Documentation Agent, AI QA Agent, Program Dashboard, EHR/PACS/SSO integration and Fleet Visibility. Compass AI is available immediately for demonstrations.
Butterfly Network (NYSE: BFLY) reported Q3 2025 results with $21.5M revenue (5% YoY) and reaffirmed full-year revenue guidance of $91M–$95M. The company reduced quarterly cash burn to a record low of $3.9M and held $144.2M cash at quarter-end. GAAP gross margin swung to a (17.5%) loss due to a $17.4M inventory write-down while adjusted gross margin rose to 63.9%. Net loss widened to $34.0M and adjusted EBITDA loss improved slightly to $8.1M. Operational milestones included ISO 27001, a JAMA clinical validation, FDA-submitted gestational-age AI, third-party app launch in Butterfly Garden, and P5.1 chip completion.
Butterfly Network (NYSE: BFLY) said its CEO and interim CFO will participate at the UBS Global Healthcare Conference in Palm Beach, FL on Tuesday, November 11, 2025 at 5:00 pm ET.
Joseph DeVivo, President, CEO & Chairman and Megan Carlson, SVP & Interim CFO will take part in a fireside chat and host one-on-one investor meetings. A live webcast will be available in the Events & Presentations section of the Butterfly investor website and will be available for replay after the event. One-on-one meetings are scheduled through UBS representatives.
Butterfly Network (NYSE:BFLY) announced it achieved multiple information-security accreditations on October 27, 2025, reinforcing its global data-protection posture.
The company obtained ISO 27001, SOC-2 Type 2, C5 Germany, and the NHS DSPT certifications, and was assessed by third-party auditor A-LIGN. Management said these certifications support enterprise-grade, secure medical imaging for hospitals and health systems across the US, UK, EU, and international markets.
The release also reiterates prior milestones: a 2024 GovRAMP Snapshot (first in medical imaging) and ongoing pursuits of full GovRAMP authorization, TX-RAMP, FedRAMP, and HITRUST CSF r2.
Butterfly Network (NYSE: BFLY) will report third quarter 2025 financial results on October 31, 2025 before market open.
Joseph DeVivo, President and CEO, and Megan Carlson, Interim CFO, will host a conference call and webcast at 8:00 AM ET on October 31 to discuss financial and operational results. The live webcast will be available on Butterfly's Investor Relations Events & Presentations page and will be archived after the call.
Telephone participants may dial in ~10 minutes early: US Toll-Free +1 833-470-1428 or US Local +1 646-844-6383 using Access Code 849303. A telephone replay is available until November 7, 2025 at US Local +1 929-458-6194 or US Toll-Free +1 866-813-9403 with Access Code 583803.
Butterfly Network (NYSE: BFLY) appointed John Doherty as Executive VP and Chief Financial Officer, effective December 8, 2025. Doherty brings over 25 years of global financial leadership including roles as CFO at Kaltura, CFO/COO at Magic Leap (secured >$1B financing and led a recapitalization), and CFO at InterXion (drove >60% revenue and EBITDA growth, led a $320M equity offering, and helped enable an $8B combination). At Verizon he participated in >$100B of strategic transactions. Management says Doherty joins as Butterfly has a successful product launch, a strengthened balance sheet, and a defined path toward breakeven. Interim CFO Megan Carlson will return to her role as Chief Accounting Officer and SVP Finance & Accounting.
Butterfly Network (NYSE:BFLY) launched an AI-powered blind-sweep Gestational Age tool in Malawi and Uganda on October 6, 2025, designed to let lower-skilled staff estimate gestational age without image interpretation or training.
The model was developed with the Gates Foundation and University of North Carolina and trained on African population data. The tool is pending US FDA review. Butterfly also reported its Gates-funded 1,000 Probe Partnership (Sep 2022–Dec 2024): 1,000 iQ+ probes deployed, 1,050+ providers trained, 697+ facilities served and 1.8M scans recorded as of July 2025.
Butterfly Network (NYSE:BFLY), a digital health company specializing in handheld ultrasound technology, has been recognized in TIME's inaugural World's Top HealthTech Companies 2025 list. The company was selected among 400 leading innovators from thousands of candidates, based on financial performance, reputation, and online engagement metrics.
Butterfly's innovative Ultrasound-on-Chip™ technology has transformed traditional ultrasound systems into a single, whole-body handheld probe. Their latest iQ3 device features AI-powered capabilities and enhanced image capture, making diagnostic imaging more accessible at the point of care. The company's technology aims to democratize ultrasound access across various healthcare settings, from resource-limited environments to advanced hospital systems.
Butterfly Network (NYSE:BFLY), a digital health company specializing in portable ultrasound technology, has appointed Victor Ku as Senior Vice President and Chief Technology Officer. Ku will join in late September 2025 to lead the company's global technology strategy, product development, and innovation roadmap.
Ku brings over 20 years of leadership experience in regulated and high-tech environments, with expertise in semiconductor-based imaging. He previously served as VP of R&D at Headwall Photonics and held senior positions at Teledyne FLIR and EFI. He holds a PhD from Oxford University and an Executive Certificate from MIT.
Butterfly Network (NYSE:BFLY) announced the publication of significant clinical trial results in JAMA demonstrating the effectiveness of their POCUS (Point-of-Care Ultrasound) program. The POCUS-CARE trial, conducted at Rutgers Robert Wood Johnson Medical School, showed that implementing Butterfly's ultrasound technology with AI assistance led to substantial improvements in hospital efficiency.
The study of 208 patients revealed that the POCUS program resulted in 246 hospital bed-days saved and $751,537 in direct cost savings. The POCUS group demonstrated a 30% reduction in expected hospital length of stay (8.3 vs. 11.9 days), with the technology changing clinical management in 35% of cases. The program focused particularly on lung ultrasound for pulmonary congestion assessment, supported by Butterfly's FDA-cleared Auto B-line Counter.